• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eli Lilly, AstraZeneca extend immuno-oncology collaboration

Eli Lilly, AstraZeneca extend immuno-oncology collaboration

October 29, 2015
CenterWatch Staff

Eli Lilly and AstraZeneca have extended their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of solid tumors.

The companies now will evaluate the safety and efficacy of a range of additional combinations across their portfolios. Lilly will lead the studies and both companies will contribute resources. Additional details and financial terms were not disclosed.

AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), will be combined with Lilly molecules that target the immune system, including TGF-beta kinase inhibitor, galunisertib, CXCR4 peptide antagonist, and an anti-CSF-1R monoclonal antibody, which also will be assessed with AstraZeneca’s anti-CTLA-4 monoclonal antibody, tremelimumab.

The companies also will explore other combinations targeting tumor drivers and resistance mechanisms, including: Lilly’s abemaciclib with Faslodex, AstraZeneca’s marketed selective estrogen receptor down regulator (SERD), and both CYRAMZA and necitumumab—Lilly’s anti-VEGFR and anti-EGFR monoclonal antibodies, respectively—with AZD9291, AstraZeneca’s investigational third-generation EGFR inhibitor.

Richard Gaynor, M.D., senior vice president, product development and medical affairs for Lilly Oncology, said, “The expansion of Lilly’s research partnership with AstraZeneca will explore the far-reaching potential of combining novel targeted therapies. Our respective pipelines afford multiple targeted options to create innovative combinations—in immuno-oncology and beyond—that we hope will lead to future cancer treatment options.”

Mondher Mahjoubi, senior vice president, global product strategy for oncology at AstraZeneca, said, “The extension of our collaboration with Lilly further supports our combination-focused oncology strategy and adds to our broad development program across small molecules and immunotherapies.”

Earlier this year, the companies entered a Phase I clinical trial collaboration to evaluate the safety and preliminary efficacy of combining durvalumab and ramucirumab as a treatment for patients with advanced solid tumors.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing